{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:02:00Z","timestamp":1791464520690,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["T32 AG000247"],"award-info":[{"award-number":["T32 AG000247"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.chest.2026.04.041","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:44:01Z","timestamp":1778579041000},"page":"1049-1059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy on Risk of Death for Individuals With Cystic Fibrosis"],"prefix":"10.1016","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9357-0034","authenticated-orcid":false,"given":"Katherine E.","family":"Kurgansky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Collaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek K.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine R.","family":"Lesko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2026.04.041_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chest.2022.07.004","article-title":"The changing epidemiology of cystic fibrosis","volume":"163","author":"Burgel","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.chest.2026.04.041_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1542\/pir.2019-0212","article-title":"Cystic fibrosis","volume":"42","author":"Dickinson","year":"2021","journal-title":"Pediatr Rev"},{"key":"10.1016\/j.chest.2026.04.041_bib3","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.lpm.2017.04.012","article-title":"The changing epidemiology and demography of cystic fibrosis","volume":"46","author":"Stephenson","year":"2017","journal-title":"Presse M\u00e9dicale"},{"key":"10.1016\/j.chest.2026.04.041_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jcf.2022.02.014","article-title":"A year in review: real world evidence, functional monitoring and emerging therapeutics in 2021","volume":"21","author":"Barr","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.chest.2026.04.041_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40272-022-00509-y","article-title":"An update on CFTR modulators as new therapies for cystic fibrosis","volume":"24","author":"King","year":"2022","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.chest.2026.04.041_bib6","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1002\/ppul.25627","article-title":"Review of CFTR modulators 2020","volume":"56","author":"Goetz","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.chest.2026.04.041_bib7","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cells11111769","article-title":"CFTR modulators in people with cystic fibrosis: real-world evidence in France","volume":"11","author":"Regard","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.chest.2026.04.041_bib8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.chest.2026.04.041_bib9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.chest.2026.04.041_bib10","first-page":"3","article-title":"CFTR modulator therapies\u2014effect on life expectancy in people with cystic fibrosis","volume":"42","author":"Balfour-Lynn","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.chest.2026.04.041_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.chest.2026.04.041_bib12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.chest.2026.04.041_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s41030-020-00115-8","article-title":"Real-world outcomes among patients with cystic fibrosis treated with ivacaftor: 2012\u20132016 experience","volume":"6","author":"Higgins","year":"2020","journal-title":"Pulm Ther"},{"key":"10.1016\/j.chest.2026.04.041_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.chest.2026.04.041_bib15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thorax-2023-220558","article-title":"Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis","volume":"79","author":"Merlo","year":"2024","journal-title":"Thorax"},{"key":"10.1016\/j.chest.2026.04.041_bib16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.chest.2026.04.041_bib17","series-title":"Cystic Fibrosis Foundation Patient Registry 2023 Annual Data Report","year":"2024"},{"key":"10.1016\/j.chest.2026.04.041_bib18","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1183\/13993003.01444-2015","article-title":"Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation","volume":"47","author":"Dilokthornsakul","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2026.04.041_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618820186","article-title":"Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor\/ivacaftor","volume":"13","author":"Rubin","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.chest.2026.04.041_bib20","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.chest.2026.04.041_bib21","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1002\/ppul.25745","article-title":"Looking toward the future: approaching care of the aging CF patient","volume":"57","author":"Sala","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.chest.2026.04.041_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1340388","article-title":"What the future holds: cystic fibrosis and aging","volume":"10","author":"Blankenship","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.chest.2026.04.041_bib23","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.chest.2026.04.041_bib24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"Von Elm","year":"2014","journal-title":"Int J Surg"},{"key":"10.1016\/j.chest.2026.04.041_bib25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available: table 1","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.chest.2026.04.041_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0060-2024","article-title":"Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review","volume":"33","author":"Hansen","year":"2024","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.chest.2026.04.041_bib27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/01621459.1996.10476908","article-title":"Multiple imputation after 18+ years","volume":"91","author":"Rubin","year":"1996","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.chest.2026.04.041_bib28","unstructured":"Greifer N. cobalt: Covariate Balance Table and Plots. 2024. R package version 4.5.5. Accessed July 29, 2026. https:\/\/ngreifer.github.io\/cobalt\/"},{"key":"10.1016\/j.chest.2026.04.041_bib29","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","article-title":"Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene","volume":"45","author":"Sosnay","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.chest.2026.04.041_bib30","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/jpm11060458","article-title":"CFTR modulators: does one dose fit all?","volume":"11","author":"Van Der Meer","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.chest.2026.04.041_bib31","article-title":"Antiretroviral adherence for adolescents growing up with HIV: understanding real life, drug delivery and forgiveness","volume":"7","author":"Foster","year":"2020","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.chest.2026.04.041_bib32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ppul.22546","article-title":"Managing treatment complexity in cystic fibrosis: challenges and opportunities: addressing complexity in cystic fibrosis","volume":"47","author":"Sawicki","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.chest.2026.04.041_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2023.05.009","article-title":"Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Wang","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.chest.2026.04.041_bib34","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1164\/rccm.201909-1845LE","article-title":"Females with cystic fibrosis demonstrate a differential response profile to ivacaftor compared with males","volume":"201","author":"Secunda","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2026.04.041_bib35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.chest.2026.04.041_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102239","article-title":"Current state of CFTR modulators for treatment of cystic fibrosis","volume":"65","author":"Despotes","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.chest.2026.04.041_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106878","article-title":"Who are the 10%? Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies","volume":"199","author":"Desai","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2026.04.041_bib38","series-title":"Cost, coverage, and the underuse of medications among people with CF","author":"Seyoum","year":"2020"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226006148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226006148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:42:04Z","timestamp":1791463324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369226006148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0012369226006148"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2026.04.041","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy on Risk of Death for Individuals With Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2026.04.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}